参考资料: [1] European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy. Retrieved October 16, 2023, from https://www.merck.com/news/european-commis...
参考资料: [1]FDAGrantsPriorityReviewtoMerck’sSupplementalBiologicsLicenseApplicationforKEYTRUDA?(pembrolizumab)MonotherapyforThird-LineTreatmentofPatientswithAdvancedSmallCellLungCancer(SCLC).RetrievedJune17,2019,fromhttps://www.businesswire.com/news/home/20190220005296/en/FDA-Grants-Priority-Review-Merck%E2%80...
原文出处:FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy https://www.mrknewsroom.com/news-release/preion-medicine...
参考文献: FDA approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) 我们特别建了“患者交流群”,欢迎肿瘤患者/家属扫描下方二维码,加入交流...
2. Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for PatientsWith Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: ResultsFrom the Phase I KEYNOTE-001 Study. J Clin Oncol, Published online on 2 June,2019. DOI: 10.1200/JCO.19.00934. ...
[2] https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-adjuvant-treatment-non-small-cell-lung-cancer 关注MORE Health,关注最新医疗资讯。如果您或者您的亲人在人生的道路上无意中碰上了肿瘤癌症、疑难...
5.Herbst R S, Baas P, Kim D W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial[J]. The Lancet, 2016, 387(10027): 1540-1550. ...
1. Siegel RL, Miller KD, Jemal A.Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. 2. Reck M, Rodriguez-Abreu D,Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-celllung cancer....
原文出处:Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Treatment for Extensive Stage Small Cell Lung Cancer 版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料...
[1] Martin Reck, et al., (2021). Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%. Journal of Clinical Oncology, DOI: 10.1200/JCO.21.00174 [2] Lung Cancer Survival Continues to Rise With ...